MULTIVALENT: THE KEY TO NEXT GENERATION CANCER TREATMENT

We are focused on developing multivalent immuno-oncology drugs capable of regulating, not blocking, multiple molecular pathways, in order to kill different cancer cell sub-types as well as reboot the immune system, all while providing patients with good quality of life. Our lead drug candidate Aneustat™ is expected to be the 1st oncology drug without toxicity, side effects or drug resistance.